Step Pharma Revenue and Competitors

Archamps,

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Step Pharma's estimated annual revenue is currently $3.1M per year.(i)
  • Step Pharma's estimated revenue per employee is $155,000

Employee Data

  • Step Pharma has 20 Employees.(i)
  • Step Pharma grew their employee count by 0% last year.

Step Pharma's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$2.8M1850%N/AN/A
Add Company

What Is Step Pharma?

Step Pharma is developing a novel class of oral nucleotide synthesis inhibitors specifically targeting cytidine triphosphate synthase 1 (CTPS1) to induce selective modulation of T and B cell populations. The discovery of CTPS1 as a potential target for immunomodulation was based on studies of humans with a CTPS1 deficiency (Martin et al., Nature. 2014 Jun 12;510(7504):288-92) providing genetic evidence that CTPS1 inhibition could be used to treat lymphoproliferative cancers and auto-immune diseases. Cytidine nucleotide triphosphate (CTP) is a precursor required for DNA synthesis, a crucial step in cell division. De novo synthesis of CTP depends on two enzymes, the CTP synthases 1 and 2 (CTPS1 and CTPS2). CTPS2 is expressed in most tissues whereas CTPS1 expression is low in all tissues including resting T and B cells, but rapidly and strongly up-regulated specifically in T and B cells following activation. Importantly, CTPS1-deficient patients only exhibit specific immunodeficiencies without other clinical problems and CTPS2 is not able to complement for the lack of CTPS1 in T and B cells. CTPS1 therefore represents a therapeutic target for a new class of highly selective immunomodulatory and oncology drugs. The anti-proliferative activity of CTPS1 inhibition has been demonstrated in multiple cancer cell lines and the pharmacokinetic/pharmacodynamic relationship has been established using several animal models of disease. Step Pharma is now preparing to take it's lead compound, STP938, forward into IND/CTA enabling studies with the aim to enter clinical development in 2021 focused on relapsed/refractory T cell lymphoma patients.

keywords:N/A

N/A

Total Funding

20

Number of Employees

$3.1M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Step Pharma News

2022-04-20 - Purdue Pharma Squares Off With DOJ Over $6 Billion ...

Now, a panel of higher-ranking judges will review the case in the last step before a Supreme Court appeal. Purdue Pharma Seeks Bankruptcy To...

2022-04-20 - Pharma needs to reach the Hispanic community, and Klick ...

I am pleased to say that we have taken some steps forward, but we still have a long way to go.” Related. 'Rigged' healthcare? Genentech survey...

2022-04-19 - Oxfam urges pharma investors to press for vaccine equity

During the annual meetings for three major vaccine players, access advocates are asking investors to step in.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$4.4M37N/AN/A
#2
$15.8M1023%N/A